Stephen R. Davis's most recent trade in Acadia Pharmaceuticals Inc was a trade of 44,782 Common Stock done . Disclosure was reported to the exchange on Aug. 16, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 44,782 | 218,302 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.28 per share. | 16 Aug 2024 | 31,747 | 186,555 (0%) | 0% | 15.3 | 485,094 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 17,333 | 173,520 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,391 | 67,173 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,391 | 166,658 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 01 May 2024 | 11,427 | 155,231 (0%) | 0% | 16.9 | 193,573 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 34,666 | 138,666 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 34,666 | 170,841 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 17,716 | 144,267 (0%) | 0% | 17.9 | 316,585 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 17,333 | 136,175 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 17,333 | 34,667 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 05 Apr 2024 | 8,858 | 161,983 (0%) | 0% | 17.9 | 158,292 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 286,451 | 286,451 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 34,666 | 136,556 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.90 per share. | 25 Mar 2024 | 17,714 | 118,842 (0%) | 0% | 17.9 | 317,081 | Common Stock |
| Acadia Pharmaceuticals Inc | Davis Stephen R. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 10,946 | 10,946 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 10,946 | 107,467 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | R. Davis Stephen | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 23 Feb 2024 | 5,577 | 101,890 (0%) | 0% | 24.7 | 137,585 | Common Stock |
| Acadia Pharmaceuticals Inc | R. Davis Stephen | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 9,528 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 9,528 | 100,253 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Davis R. Stephen | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 06 Jan 2024 | 3,732 | 96,521 (0%) | 0% | 30.0 | 111,811 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 100,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 14 Jul 2023 | 100,000 | 36,695 (0%) | 0% | 30.0 | 3,004,350 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.77 per share. | 14 Jul 2023 | 100,000 | 136,695 (0%) | 0% | 20.8 | 2,077,000 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 11 Jul 2023 | 55,104 | 36,695 (0%) | 0% | 25.1 | 1,380,449 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 Jul 2023 | 16,498 | 91,799 (0%) | 0% | 25 | 412,450 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 295,503 | 295,503 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 89,564 | 89,564 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 15,625 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 15,625 | 116,103 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.18 per share. | 29 Apr 2023 | 7,806 | 108,297 (0%) | 0% | 21.2 | 165,331 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 17,333 | 52,000 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2023 | 17,333 | 109,060 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 05 Apr 2023 | 8,582 | 100,478 (0%) | 0% | 18.2 | 155,849 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 10,945 | 95,578 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 10,945 | 21,892 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 23 Feb 2023 | 3,851 | 91,727 (0%) | 0% | 18.8 | 72,322 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 9,528 | 9,528 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 9,528 | 88,537 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.13 per share. | 06 Jan 2023 | 3,904 | 84,633 (0%) | 0% | 17.1 | 66,877 | Common Stock |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 52,032 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,938 | 81,813 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,938 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.81 per share. | 15 Oct 2022 | 2,804 | 79,009 (0%) | 0% | 15.8 | 44,331 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 15,625 | 81,358 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 15,625 | 15,625 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 29 Apr 2022 | 5,483 | 75,875 (0%) | 0% | 18.2 | 99,691 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 277,331 | 277,331 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 237,931 | 237,931 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 69,333 | 69,333 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 10,945 | 69,661 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 10,945 | 32,837 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 23.80 per share. | 23 Feb 2022 | 3,928 | 65,733 (0%) | 0% | 23.8 | 93,486 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 9,527 | 62,434 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 9,527 | 19,056 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 23.05 per share. | 06 Jan 2022 | 3,718 | 58,716 (0%) | 0% | 23.1 | 85,700 | Common Stock |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 10,452 | 13,452 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 5,938 | 55,869 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 5,938 | 5,938 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.41 per share. | 15 Oct 2021 | 2,963 | 52,906 (0%) | 0% | 17.4 | 51,586 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 15,625 | 57,162 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 15,625 | 31,250 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 29 Apr 2021 | 7,850 | 49,312 (0%) | 0% | 20.3 | 159,591 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 161,230 | 161,230 | - | - | Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 43,782 | 43,782 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 40,625 | 40,625 | - | - | Employee Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 40,625 | 40,625 | - | - | Employee Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 31,250 | 43,059 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 23,750 | 23,750 | - | - | Employee Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.61 per share. | 04 Feb 2021 | 14,195 | 28,900 (0%) | 0% | 50.6 | 718,409 | Common Stock |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 9,527 | 28,583 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 9,527 | 27,966 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.34 per share. | 06 Jan 2021 | 3,484 | 24,482 (0%) | 0% | 53.3 | 185,837 | Common Stock |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 3,000 | 3,000 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 5,937 | 17,746 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 5,937 | 11,876 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Stephen R. Davis | Director, CEO | Sale of securities on an exchange or to another person at price $ 42.56 per share. | 15 Oct 2020 | 2,960 | 14,786 (0%) | 0% | 42.6 | 125,978 | Common Stock |
| Heron Therapeutics Inc | Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 765 | 765 | - | - | Stock Option (Right to Buy) |